Ketamine Update with Brandon Kitay, M.D. - a podcast by David Puder, M.D.

Esketamine is the first non-monoaminergic based medication which is FDA approved and indicated for treatment refractory depression. A longer duration of undertreated depression is associated with poor longitudinal functional outcomes. Instead of cycling patients through monoaminergic antidepressant trials and cognitive behavioral therapy approaches, according to Dr. Kitay, providers should consider treatments like esketamine much sooner in the treatment course.

Link to full blog

Link to Resource Library. 

Further episodes of Psychiatry

Further podcasts by David Puder, M.D.

Website of David Puder, M.D.